Direct modulation of NOS activity through isoform-specific inhibitors or enhancers, such as iNOS inhibitors and eNOS activators, has shown efficacy in preclinical models of inflammation, cardiovascular diseases, and neurodegeneration. This evidence concerns the gene NOS3 and cardiovascular disorder.